Introduction {#s1}
============

Despite existing evidence that suggests its safety in patients with acute abdominal pain without the risk of obscuring the diagnosis \[[@R01]\], many physicians are still reluctant to use opioid analgesia in this situation \[[@R02]\].

We aimed to update existing evidence on the use of any type of opioid analgesia for acute abdominal pain using both conventional and network meta-analyses. Furthermore, for the first time to our knowledge, we evaluate direct and indirect evidence with different types of opioid analgesics and compare them using network meta-analysis. The primary outcome was the rate of incorrect diagnosis.

Methods {#s2}
=======

This systematic review and network meta-analysis were carried out in accordance with the guidelines set out in the Preferred Reporting Items for Systematic Reviews & Meta-Analyses (PRISMA) checklist \[[@R03]\].

Literature search {#s2a}
-----------------

A systematic literature search of articles published in the last 30 years was performed using the EMBASE, MEDLINE (PubMed), Cochrane Library, and Google Scholar databases using free text and Medical Subject Headings (MeSH) search terms (opioid analgesia or analgesics; acute abdominal pain or surgical pain; acute appendicitis; surgical diagnosis or definite diagnosis; morphine; randomized controlled trial). A grey literature search at the website clinicalTrials.gov was also performed. References of retrieved articles were checked manually for further relevant studies. Disagreement between authors was resolved by consensus.

Study selection, inclusion and exclusion criteria {#s2b}
-------------------------------------------------

We included randomized controlled trials (RCTs) that compared opioid analgesia of any type vs. placebo for acute surgical pain before definitive surgical diagnosis in patients older than 12 years, and if the mean age of subjects in the study sample was within the adult range. Non-randomized studies, reviews, and narrative articles were excluded.

Data extraction and outcomes {#s2c}
----------------------------

Two reviewers (PG and NA) independently extracted the following summary data from the included studies: name of authors; number of patients; age; type of opioid analgesia; pre-treatment intensity of the pain; change in the intensity of the pain; rate of errors in treatment; and rate of incorrect diagnosis.

Risk of bias assessment of included studies {#s2d}
-------------------------------------------

Two authors (PG, NA) independently assessed the risk of selection, performance, attrition, detection, and reporting bias for each included study. The above parameters were categorized as high, low, or unclear risk according to the Cochrane Handbook for Systematic Reviews of Interventions \[[@R04]\].

Statistical analysis {#s2e}
--------------------

Statistical analysis was conducted using both Stata (version 15, Stata Corp LP, Collage Station, TX, USA) and Review Manager 5.3 software (The Cochrane Collaboration, Oxford, England). The I^2^ test was performed with cut-off values set at 25%, 50%, and 75% to indicate low, moderate, and high levels of heterogeneity respectively \[[@R05]\]. In such cases, we performed analysis using both fixed- and random-effects models and the conclusions were compared; the random-effects model was used preferentially in case of discrepancies between the two models. In case of I^2^ values less than 25%, the fixed-effect model was used throughout.

Dichotomous variables were analyzed based on odds ratios (OR) with 95% confidence intervals (CIs). For the analyzed outcomes, the reference categories were selected to favour opioid analgesia if the OR was \< 1. Continuous variables were compared based on both the mean difference (MD) and the standardized mean difference (SMD). For studies that did not report the means and variances for the two groups, these values were estimated from the median, range, and the sample size where possible, using the technique described by Hozo et al \[[@R06]\]. For all analyses, the significance level was set at P \< 0.05.

Network meta-analysis was performed using hierarchical random-effects models \[[@R07]\]. A fixed-effects model was also used to estimate whether any discrepancy could be demonstrated between the results of the two models. Quantitative data synthesis of the connected network of studies was conducted using the software package WinBUGS (version 1.4.3, MRC Biostatistics Unit, Cambridge, UK) \[[@R08]\]. Pooled estimates were obtained using the Markov chain Monte Carlo method. Minimally informative priors with vague normal prior distributions were used. For each model, 200,000 simulations were generated for the two sets of different initial values, and the first 5,000 were discarded as the burn-in period. The Brooks-Gelman-Rubin statistic was used for the assessment of convergence. The point estimate was defined as the median of the posterior distribution based on 200,000 simulations; the corresponding 95% credible intervals (CrIs) were obtained using the 2.5th and 97.5th percentiles of the posterior distribution, which can be interpreted in a similar way as 95% CIs. Inconsistency and heterogeneity of direct and indirect evidence for the five approaches were estimated.

Sensitivity analysis {#s2f}
--------------------

Analyses of primary and secondary outcomes were conducted using both random- and fixed-effect models in order to assess the impact of heterogeneity on the results. Direct and indirect evidence of the five pain management approaches were estimated and compared. Publication bias was not estimated because less than 10 studies were included in each evaluated outcome \[[@R9]\].

Results {#s3}
=======

Search strategy and study characteristics {#s3a}
-----------------------------------------

Twelve studies, which included 1,314 patients, were selected from a pool of 141 studies \[[@R10]-[@R21]\]. From the 25 full-text assessed studies, 13 were excluded for the following reasons: four studies used non-opioid analgesia, four included pediatric population, two were retrospective studies, two were case-controlled studies, and data extraction was difficult in one study ([Fig. 1](#F1){ref-type="fig"}) \[[@R03]\]. Eight studies compared morphine to placebo, two studies compared tramadol to placebo, one study compared papaveretum to placebo and one, pethidine to placebo ([Table 1](#T1){ref-type="table"}).

![Flow diagram of the search strategy \[[@R03]\].](jocmr-11-121-g001){#F1}

###### : Study Characteristics and Risk of Bias

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                        Number of patients OA - PL   Age OA - PL, mean, SD                          Type of opioid        Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment
  ----------------------------- ---------------------------- ---------------------------------------------- --------------------- ---------------------------- ------------------------ ---------------------------------------- --------------------------------
  Attard, 1992, UK              50 - 50                      Over 16                                        Papaveretum 20 mg     High risk                    Unclear                  High risk                                High risk

  Pace, 1996, USA               35 - 36                      Over 18\                                       Morphine 10 mg        Low risk                     Unclear                  Low risk                                 High risk
                                                             44 ± 19 - 41 ± 18\                                                                                                                                                  
                                                             P = 0.496                                                                                                                                                           

  LoVecchio, 1997, USA          22 - 16                      Over 18                                        Morphine 5 or 10 mg   Low risk                     High risk                Low risk                                 High risk

  Vermulen, 1999, Switzerland   175 - 165                    Over 16                                        Morphine 10 mg        High risk                    High risk                High risk                                High risk

  Mahadevan, 2000, Singapore    33 - 33                      Over 16\                                       Tramadol 1 mg/kg      Low risk                     Low risk                 Unclear                                  Unclear
                                                             27 ± 11 - 29 ± 13\                                                                                                                                                  
                                                             P = 0.502                                                                                                                                                           

  Thomas, 2003, USA             38 - 36                      Over 18\                                       Morphine 15 mg        Unclear                      High risk                High risk                                Low risk
                                                             39 ± 4.5 - 39 ± 6.5\                                                                                                                                                
                                                             P = 1.00                                                                                                                                                            

  Gallagher, 2006, USA          78 - 75                      Over 21\                                       Morphine 0.1 mg/kg    Low risk                     Low risk                 Low risk                                 Low risk
                                                             47 ± 17 - 45 ± 17\                                                                                                                                                  
                                                             P = 0.468                                                                                                                                                           

  Amoli, 2008, Iran             35 - 36                      Over 14\                                       Morphine 0.1 mg/kg    Low risk                     Low risk                 Low risk                                 Low risk
                                                             26.7 ± 10 - 23.9 ± 7\                                                                                                                                               
                                                             P = 0.175                                                                                                                                                           

  Amini, 2012, Iran             53 - 53                      Over 16\                                       Pethidine 1 mg/kg     High risk                    High risk                High risk                                High risk
                                                             30 ± 10 - 29 ± 10\                                                                                                                                                  
                                                             P =0.608                                                                                                                                                            

  Güngör, 2012, Turkey          39 - 41                      Over 21\                                       Morphine 0.1 mg/kg    High risk                    High risk                Unclear                                  Low risk
                                                             73 ± 7 - 73 ± 8\                                                                                                                                                    
                                                             P = 1.00                                                                                                                                                            

  Aghamohammadi\                60 - 60                      Over 12\                                       Morphine 0.1 mg/kg    Low risk                     Low risk                 Low risk                                 Unclear
  2012, Iran                                                 31 ± 10 - 35 ± 10\                                                                                                                                                  
                                                             P = 0.054                                                                                                                                                           

  Agodirin, 2013, Nigeria       46 - 49                      Over 18                                        Tramadol 100 mg       Low risk                     Low risk                 Low risk                                 High risk

  Pooled differences            664 - 650\                   OR = 0.09 (-1.31, 1.48), P = 0.90, I^2^ = 5%                         Low risk seven studies       Low risk five studies    Low risk six studies                     Low risk four studies
                                total 1,314                                                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OA: opioid analgesia; PL: placebo; SD: standard deviation.

Patient demographics {#s3b}
--------------------

There was no evidence of significant difference in age between the intervention and control cohorts. The mean age in each study was within the adult range, although some of the studies included patients over 12, 14, and 16 years old ([Table 1](#T1){ref-type="table"}).

Results from pairwise meta-analysis of primary and secondary outcomes {#s3c}
---------------------------------------------------------------------

### Incorrect diagnosis {#s3c1}

Nine of 12 studies reported incorrect diagnosis \[[@R10]-[@R13], [@R15]-[@R16], [@R18]-[@R19], [@R21]\]. There was no evidence of a statistically significant difference in the rate of incorrect diagnoses between the opioid analgesia cohort and the placebo cohort (OR = 0.79 (0.54 to 1.17), P = 0.24, I^2^ = 13%) ([Fig. 2](#F2){ref-type="fig"}).

![Forest plot illustrating incorrect diagnosis.](jocmr-11-121-g002){#F2}

### Pre-treatment intensity of pain {#s3c2}

Studies reported pain using the visual analogue scale (VAS). Eleven out of 12 studies reported pre-treatment intensity of pain \[[@R10]-[@R20]\]. There was no evidence for statistically significant difference between the opioid analgesia cohort and the placebo cohort (MD = 0.43 (-0.05 to 0.91), P = 0.08, I^2^ = 81%).

### Post-treatment intensity of pain {#s3c3}

Reduction in pain was observed in both cohorts. However, reduction in the intensity of pain was significantly greater in the opioid analgesia cohort compared to the placebo cohort (MD = -1.76 (-2.50 to -1.03), P \< 0.001, I^2^ = 94%).

Results from the network meta-analysis {#s3d}
--------------------------------------

The network of evidence of the five pain management approaches was demonstrated using a figure of star with four radiuses. Vertices represent the pain management strategy and sample size. Lines represent head-to-head comparisons with line thickness being proportional to the number of studies included ([Fig. 3a](#F3){ref-type="fig"}).

![Plot showing (a) evidence of treatment approaches and (b) direct and indirect evidence of the treatment approaches. PL, placebo; MR, morphine; TR, tramadol; PV, papaveretum; PTH, pethidine.](jocmr-11-121-g003){#F3}

### Direct evidence of incorrect diagnosis with any type of opioid analgesia vs. placebo {#s3d1}

There was no evidence of statistically significant differences in incorrect diagnosis between the cohorts of morphine vs. placebo, tramadol vs. placebo and pethidine vs. placebo: OR (CI) = 0.96 (0.64 to 1.44), 5.56 (0.26 to 119), and 0.82 (0.35 to 1.96), respectively. Moreover, there was significantly fewer incorrect diagnosis with papaveretum compared to the placebo cohort (OR = 0.19 (0.04 to 0.93)) ([Fig. 3b](#F3){ref-type="fig"}).

### Indirect evidence of incorrect diagnosis with tramadol, papaveretum, and pethidine vs. morphine {#s3d2}

There was no evidence of significant difference in incorrect diagnosis between the cohorts of tramadol vs. morphine, papaveretum vs. morphine, and pethidine vs. morphine: OR (CI) = 5.78 (0.26 to 127), 0.20 (0.04 to 1.01), and 0.86 (0.33 to 2.22), respectively ([Fig. 3b](#F3){ref-type="fig"}).

### Indirect evidence of incorrect diagnosis with papaveretum, and pethidine vs. tramadol {#s3d3}

There was no evidence of significant difference in incorrect diagnosis between the cohorts of papaveretum and pethidine compared to tramadol: OR (CI) = 0.03 (0.00 to 1.08) and 0.15 (0.01 to 3.57), respectively ([Fig. 3b](#F3){ref-type="fig"}).

### Indirect evidence of incorrect diagnosis with pethidine vs. papaveretum {#s3d4}

There was no evidence of significant difference in incorrect diagnosis between the cohort of pethidine compared to papaveretum (OR = 4.34 (0.71 to 26.46)) ([Fig. 3b](#F3){ref-type="fig"}).

Risk of bias of RCTs {#s3e}
--------------------

Seven studies were assessed to be at low risk in random sequence generation, five were considered to be at low risk of allocation concealment, six were considered to be at low risk in the blinding of participants and personnel, and four studies were considered at low risk in the blinding of outcome assessment. Studies by Gallagher and Amoli were assessed to be at low risk in all the above domains ([Table 1](#T1){ref-type="table"}).

Discussion {#s4}
==========

The aim of this study was to estimate direct and indirect evidence of the impact of any type of opioid analgesia compared to placebo on acute abdominal pain before the establishment of definitive diagnosis using network meta-analysis.

There was no significant difference in the intensity of pain between the two cohorts, although a placebo effect was demonstrated. However, there was a significant reduction in the intensity of pain with opioid analgesics.

Despite pre-existing evidence, many clinicians are reluctant to use opioid analgesia in acute abdominal pain based on the belief that it impairs diagnostic accuracy \[[@R01], [@R02]\]. The present study demonstrates that there is no significant difference in the rate of incorrect diagnosis between the opioid analgesic cohort and the placebo cohort.

Furthermore, in the present study direct and indirect evidence were estimated using network meta-analysis. The results of the direct evidence of network meta-analysis further justify the results of the conventional meta-analysis. Furthermore, for the first time to our knowledge, in the present study, all possible comparisons between four opioid analgesics were estimated based on indirect evidence provided by network meta-analysis. Consequently, the results demonstrated that there is no evidence of the superiority of one opioid analgesic over the other ([Fig. 3b](#F3){ref-type="fig"}). Based on the results of the present indirect evidence, we can conclude that there is no need for further investigation in order to estimate the superiority of one opioid analgesic over the other, with all four opioids demonstrating a similar effect size.

To the best of our knowledge, this is the first network meta-analysis and the results of the present study further corroborate with the results of the previous Cochrane review \[[@R01]\]. Moreover, the present study is more representative because it includes studies from all continents ([Table 1](#T1){ref-type="table"}).

Limitations {#s4a}
-----------

However, the results of the present study should be interpreted cautiously, because it has several limitations. RCTs from the 1990s are not of good quality overall; none of them blinded the outcome assessors and their randomization and allocation concealment were inadequate. Another limitation of all the included studies is the small sample size, different clinical endpoints and variable lower age limits which contribute to study heterogeneity ([Table 1](#T1){ref-type="table"}). Therefore, an adequately powered, multicentre RCT with common objectives and a more homogenous population will shed further light on this topic.
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